An Open-Label, 8-week Trial of Bupropion Hydrochloride Extended Release (Wellbutrin XL®) In Patients With Major Depressive Disorder (MDD) With Atypical Features. (WellbutrinXL)

NCT01477931 Phase 4 COMPLETED

The aims of this study are 1) to examine the clinical utility of bupropion hydrochloride extended release (Wellbutrin XL®) in patients with Major Depressive Disorder (MDD) with atypical features; 2) to evaluate the tolerability of bupropion hydrochloride extended release (Wellbutrin XL®) in patients with MDD with atypical features.

Details

Lead sponsor	Chi-Un Pae
Phase	Phase 4
Status	COMPLETED
Enrolment	50
Start date	2010-11
Completion	2011-09

Conditions

• Depressive Disorder, Major

Interventions

• Bupropion extended release

Primary outcomes

• HAM-D-29 scores(Hamilton Depression Rating Scale 29) — 8 weeks
  Changes in HAM-D-29 scores from baseline to the end of treatment.

Countries

South Korea